The bacterial division Synergistes represents a poorly characterized phylotype of which only a few isolates have been cultured, primarily from natural environments. Recent detection of Synergistes-like sequence types in periodontal pockets and caries lesions of humans prompted us to search the R. M. Alden culture collection (Santa Monica, Calif.) for biochemically unidentifiable, slow-growing, obligately anaerobic gram-negative bacilli. Here we report on five clinical isolates cultured from peritoneal fluid and two isolates from soft-tissue infections that together constitute three separate evolutionary lineages within the phylogenetic radiation of the division Synergistes. One of these clusters was formed by the peritoneal isolates and had an 85% similarity to Synergistes jonesii, the first described Synergistes species, which was isolated from the rumen of a goat. The isolates from soft-tissue infections, on the other hand, formed two distinct lineages moderately related to each other with a similarity of approximately 78%. In addition, by using a newly designed 16S rRNA gene-based PCR assay with intended target specificity for Synergistes, we found that the dominant phylotype from a fecal sample was nearly identical to that of the strains obtained from peritonitis. Conversely, sequence types detected in periodontal pockets formed a separate cluster that shared a similarity of only 80% with the soft-tissue isolates. These findings suggest a high diversity of medically important Synergistes clades that apparently are unique to individual ecological niches in the human body. In conclusion, we now have available the first characterized human isolates of the division Synergistes which are colonizing, and probably infecting, several sites in the human body.
During the past two decades, the breadth of bacterial diversity now recognized has increased to more than 40 identifiable phylogenetic branches or divisions (6) . Many of these divisions are defined exclusively by environmentally retrieved 16S rRNA gene sequences ("candidate divisions" [6] ) or by only a small number of cultured isolates. A typical example of the latter is the "Synergistes" division, which is still a poorly described phylotype (4) . For instance, of the 124 16S rRNA gene sequences displayed in the Synergistes GenBank database, only two are derived from actual isolates: Synergistes jonesii, accession number L08066, isolated from the rumen of a goat (1) , and Synergistes sp. strain P4G_18P1, accession number AY207056, isolated from the oral cavity (W. G. Wade and A. de Lillo, unpublished data). On the other hand, recent molecular methods-based approaches have provided evidence that these organisms are widespread in nature (4) . Synergistes-like 16S rRNA gene sequences have been found in molecular inventories of several pollution-removal anaerobic digestors (8, 18, 23) , as well as termite hindguts (5, 16) , pig intestinal tract (9) , petroleum reservoirs (17, 21) , and the human subgingival ecosystem (7, 14) . Using 16S rRNA gene-targeted PCR, Godon et al. (4) recently explored 93 anaerobic environments, including mesophilic and thermophilic anaerobic digestors, curd, pig slurry, compost, soil of 23 different types or locations, and the guts of 49 different animals, plus four specimens from human sources, and found Synergistes present in 95% of the ecosystems analyzed, though its proportion was generally below 1% (4, 12) . The sequences from animal sources formed their own clustered groups, as did the sequences from digestors, soil, and human subgingival plaque, suggesting that phylogenetically defined subgroups of Synergistes group organisms (SGOs) occupy their own individual ecological niches (4) .
Despite their recent discovery at various infected sites in the oral cavity (14, 19) , human-associated SGOs have remained largely uncharacterized. In order to extend our knowledge of their ubiquity and phylogenetic diversity, we looked for possible candidates from the clinical culture collection of the R. M. Alden Research Laboratory, Santa Monica, Calif., focusing on isolates that could not be biochemically identified as members of any previously described species. The seven strains that we found constitute distinct lineages within the division of Synergistes. Here we provide a phylogenetic characterization of these isolates along with a first profile of biochemical activity and antimicrobial susceptibility. We have also developed a specifically targeted 16S rRNA gene PCR system to directly assess the incidence and phylotypes of SGOs in various human sites, such as feces and subgingival plaque.
MATERIALS AND METHODS
Selection of bacterial strains. Initially, 10 biochemically unidentifiable, slowgrowing anaerobic gram-negative rods were selected from the culture collection of the R. M. Alden Research Laboratory, Santa Monica, CA. This laboratory, previously located at the Santa Monica University of California-Los Angeles Medical Center and now an independent facility, was founded in 1980 in order to characterize the etiology of human infectious diseases, focusing on anaerobic and fastidious bacteria. Through 16S rRNA gene sequencing (described below), seven strains were found to be phylogenetically affiliated with members of the Synergistes division, while three isolates were affiliated with Proteobacteria and were therefore excluded from this study. The seven SGOs were from various sources: sacral wound soft-tissue infection (strain RMA 10849), diabetic foot soft-tissue infection (RMA 14551), and peritoneal fluid (RMA 14605, RMA 15677, RMA 16088, RMA 16290, and RMA 16406). All strains were subcultured at the R. M. Alden Research Laboratory on brucella agar (Anaerobe Systems, Morgan Hill, CA) and incubated at 37°C under anaerobic conditions. Biochemical testing. Biochemical tests performed at the R. M. Alden Research Laboratory included determination of susceptibility to special potency disks of kanamycin (1,000 g), vancomycin (5 g), and colistin (10 g) as well as catalase, spot indole, nitrate reduction, growth on bile, urease, growth stimulation with formate/fumarate, and SIM (sulfide-indole-motility), as described previously (22) . In addition, an enzymatic profile was determined using the RapID ANA II system (Remel, Lenexa, KS) according to the manufacturer's instructions.
Antimicrobial testing. All SGOs were tested against 14 antimicrobial agents, including ampicillin-sulbactam (Pfizer, Roerig Division, Groton, CT); amoxicillin-clavulanate and ticarcillin-clavulanate (Glaxo SmithKline, Philadelphia, PA); piperacillin-tazobactam (Wyeth Laboratories, Pearl River, NY); ertapenem, imipenem, and cefoxitin (Merck & Co., Rahway, NJ); ceftriaxone (Roche Laboratories Inc., Nutley, NJ); moxifloxacin (Bayer Corporation, Mt. Prospect, IL); levofloxacin (Johnson & Johnson, Springhouse, PA); chloramphenicol and penicillin (Sigma, St. Louis, MO); clindamycin (Voigt Global Distributing, Kansas City, MO); and metronidazole (Searle Inc., Skokie, IL). Antimicrobial powders were reconstituted according to the manufacturers' instructions, and serial twofold dilutions were made to prepare the plates. Susceptibility testing was performed by the standard agar dilution method according to the procedure described in CLSI (formerly NCCLS) M11-A6 (3).
Collection of fecal and oral samples. Fecal and oral samples were collected for cultivating-independent molecular methods-based screening of SGOs. (i) Fecal samples were obtained from three healthy adult subjects. The donating individuals, one female (age 47) and two males (age 26 and 33), were without special diet and were free of medication. (ii) Subgingival plaque was initially investigated from three patients with chronic periodontal disease (CP) and from two patients with aggressive periodontal disease (AP). From these five plaque samples two samples, CP1177 and AP1156, were selected to generate clone libraries for detailed analysis. Sample CP1177 was obtained from a periodontal pocket of a 45-year-old male with a pocket depth of 6 mm, while AP1156 was obtained from a periodontal pocket of a 53-year-old male with a pocket depth of 7 mm.
DNA extraction. Microbial DNA from subgingival plaque and fecal samples, as well as DNA from pure cultures, was extracted and purified with a Qiamp DNA Mini kit ("tissue protocol"; QIAGEN, Hilden, Germany) according to the manufacturer's instructions, with one modification: 0.8 g of zirconia-silica beads (0.1 mm in diameter; Biospec, Bartlesville, OK) was added prior to the addition of Proteinase K. Samples were then agitated in a FastPrep FP 120 instrument (Qbiogene, Carlsbad, CA) at 6.5 m/s for 45 s. All further steps followed the original protocol. The DNA concentration (A 260 ) and the purity (A 260 /A 280 ) were calculated using a Gene Quant II photometer (Pharmacia Biotech, Cambridge, England).
Probe design. The 16S forward primer Syn360F (5Ј GGAATATTGGGCAA TGGG 3Ј), starting at Escherichia coli position 360, as well as the 16S reverse primer Syn961R (5Ј GTTCTTCGGTTTGCATCG 3Ј), starting at Escherichia coli position 961, were designed based on regions of identity within 16S rRNA genes following the alignment of 75 Synergistes sequences (including the isolates from this study) and using the function "probe design" of the ARB software package (10) . The primers were tested for possible cross-hybridization with the 16S rRNA genes of bacterial strains unrelated to the T ), as well as four fecal isolates, Bacteroides fragilis AC-1, Clostridium perfringens AC-2, Enterococcus faecalis AC-3, and Escherichia coli AC-4, obtained from the Department of Medical Microbiology, University Hospital RWTH Aachen, Germany. Using the PCR temperature profile outlined below, no PCR product was obtained for these non-target bacterial strains.
PCR amplification. For generating almost complete 16S rRNA gene information of approximately 1,400 bp in length from Synergistes strains, PCR amplification of the 16S rRNA gene was performed on an Eppendorf thermocycler (Mastercycler personal) in a volume of 50 l containing 1ϫ PCR buffer, 1.5 mM MgCl 2 , 2 U Taq polymerase, 0.2 mM each of dATP, dCTP, dGTP, and dTTP (Roche Applied Science, Penzberg, Germany), 100 nM of each primer, and 1 l of template DNA (approximately 50 ng). Universal primers used were PF1 (5Ј AGAGTTTGATCCTGGCTCAG 3Ј) and PR1 (5Ј GGCTACCTTGTTACG ACTT 3Ј) (20) , with PCR cycling conditions of 94°C for 2 min, followed by 25 cycles of 94°C for 60 s, 55°C for 60 s, and 72°C for 1.5 min, with a final extension of 72°C for 10 min.
Amplification and detection of Synergistes 16S rRNA genes from total community DNA directly extracted from oral samples (periodontal pockets) was performed on a LightCycler 2.0 (Roche Applied Science) using LightCycler FastStart DNA Master plus SYBR Green I in a total volume of 20 l. Final reactions contained 100 nM of the primers Syn360F and Syn961R (see above) and 1 l of template DNA (approximately 50 ng) to give an approximately 600-bp amplification product. PCR cycling conditions included a "touch-down" temperature profile of 95°C for 10 min, followed by 10 cycles of 95°C for 10 s, 66°C for 7 s (with a decrease of 0.2°C after each cycle), 72°C for 25 s, and 40 cycles each of 95°C for 10 s, 64°C for 7 s, and 72°C for 25 s. Melting curve analysis was performed to determine the melting point of the amplification products and to assess reaction specificity. The presence of single DNA bands of the expected size was also confirmed by agarose gel electrophoresis.
Finally, for the amplification and detection of Synergistes 16S rRNA genes from total community DNA directly extracted from fecal samples, a nested PCR approach was necessary. The first round of amplification was performed using the universal primers PF1 and PR1 under the conditions described above with 1 l of template DNA (approximately 50 ng). Likewise, the second round of amplification (nested PCR) was performed using the primers Syn360F and Syn961R under the conditions described above, using as template 1 l of the PCR product from the first round.
Cloning and sequencing. PCR products were cloned using a TOPO TA cloning kit (Invitrogen Corp., San Diego, CA) following the protocol of the manufacturer. The preparation of plasmid DNA of randomly selected clones, PCR amplification of cloned inserts, and nonradioactive sequencing were carried out as described previously (20) . Prior to sequencing, PCR products were purified using the QIAGEN Purification kit according to the manufacturer's instructions. Bidirectional sequencing was performed using a Big Dye-Deoxy terminator cycle sequencing kit (Applied Biosystems) and an automatic capillary DNA sequencer (API Prism 310; Applied Biosystems). While the sequences for the clinical isolates and for the fecal samples could be determined by direct sequencing (i.e., without cloning) of the respective PCR products, sequences for the periodontal samples were determined from cloned PCR products, as direct sequencing led to ambiguous sequences.
Phylogenetic analysis. The identities of the 16S rRNA gene sequences were confirmed by searching the international sequence databases using the BLAST program (http://www.ncbi.nlm.nih.gov/BLAST/). Sequences were subsequently integrated within the ARB program package (10) and analyzed and edited using its alignment tools. Phylogenetic tree reconstruction was done using the neighbor-joining approach with Jukes Cantor correction. The robustness of the tree topology was verified through calculating bootstrap values for the neighborjoining tree and through comparison with the topology of a maximum likelihood tree, calculated by using the default settings in ARB.
Nucleotide sequence accession numbers. The gene sequences determined in this study (i.e., 16S rRNA gene sequences of clinical isolates, fecal samples, and periodontal clones) have been deposited in the EMBL, GenBank, and DDBJ nucleotide sequence databases under accession numbers DQ412708 to DQ412725.
RESULTS
Biochemical characteristics and antimicrobial susceptibility of Synergistes isolates. The seven clinical isolates investigated in this study were morphologically similar to slow-growing anaerobes from the division Proteobacteria (e.g., dissimilatory sulfate-reducers) but with discrepancies in key biochemical identification tests. Biochemical characteristics of these strains are compiled in Table 1 in comparisons with Desulfovibrio spp. and other phenotypically related species which have been described previously (22) . All seven Synergistes strains were kanamycin susceptible but resistant to vancomycin and colistin. Strains RMA 16088, RMA 14605, RMA 15677, RMA 16406, and RMA 16290 (all from peritoneal fluid) were bile resistant, whereas the two isolates from soft-tissue infections (RMA (Table 1) . According to the RapID ANA II identification system, RMA 14551 was the only strain able to hydrolyze glycine-␤-naphthylamide, whereas RMA 10849 and the other strains were completely negative in all enzymatic reactions. This is in contrast to most of the other phenotypically similar anaerobic gram-negative bacilli tested (Table 1 ). All seven Synergistes group isolates were susceptible to ampicillin-sulbactam, amoxicillin-clavulanate, ticarcillin-clavulanate, ertapenem, imipenem, cefoxitin, ceftriaxone, levofloxacin (MICs, Յ0.06 to 4 g/ml; breakpoints for anaerobes have yet to be established), chloramphenicol, clindamycin, and metronidazole. However, in contrast to the soft-tissue isolates (RMA 10849 and 14551), the five levofloxacin-susceptible isolates of intestinal origin were resistant to moxifloxacin (MICs, Ն8 g/ml). In addition, one isolate (RMA 14605) was penicillin resistant (MIC Ͼ 4 g/ ml) and nonsusceptible (intermediate) to piperacillin-tazobactam (MIC ϭ 64 g/ml).
Phylogenetic analysis of novel strains. Phylogenetic analysis was based on nearly full-length sequences (approximately 1,400 bp), except for strains RMA 16406 and RMA 15677 (approximately 500 bp). The identities of all sequences as belonging to the division Synergistes were confirmed by searching the GenBank database. Phylogenetic tree reconstruction was performed by including a representative set of publicly available reference sequences. Figure 1 depicts the evolutionary relationships of the clinical isolates at the interdivision level, while Fig. 2 shows the phylogenetic relationships among Synergistes sequence types. The five strains isolated from peritoneal fluid formed a coherent cluster (cluster I) moderately related to Synergistes jonesii, with approximately 85% similarity (Fig. 2) . Within this cluster, strains RMA 16088, RMA 14605, and RMA 15677 grouped tightly with each other, while strains RMA 16406 and RMA 16290 showed a similarity of approximately 95% to the other three strains. In contrast, strain RMA 14551 (diabetic foot) formed a distinct lineage distantly related to cluster I and with approximately 82% similarity to the oral strain Synergistes sp. strain P4G_18 as its closest relative. Likewise, strain RMA 10849 (sacral wound) branched separately, showing a similarity of approximately 90% to its closest relative, the oral isolate E3_33 (deposited in the GenBank database as "Flexistipes sp. E3_33"). Although they represent different lineages, strains RMA 14551 and RMA 10849 shared a common interior branching point with a sequence similarity of approximately 78% and were thus together designated cluster II. In summary, all seven clinical isolates fell within the phylogenetic radiation of Synergistes and represented at least three distinct evolutionary lineages ( Fig. 1 and 2) .
Cultivation-independent detection of SGOs in human samples. As known colonizers of the animal gut, we suspected that SGOs were also present in the human intestinal tract. Total microbial community DNA from three unique fecal samples was used for PCR amplification. At first, using the primers specifically designed for the 16S rRNA genes of Synergistes, no PCR product was obtained for any of the samples. However, after preamplification using universal 16S rRNA primers and subsequently performed nested PCR with Synergistes-specific primers, a PCR amplification product of the correct fragment size was obtained for one out of three samples tested. An ambiguity-free sequence was obtained by direct sequencing of the PCR product, which could then be assigned to Synergistes through GenBank database research. Phylogenetic treeing analysis grouped this sequence type, "Syn1," tightly to cluster I, the clade exclusively represented by the clinical isolates from peritoneal fluid, with a similarity of Ͼ99% to strain RMA 16088 (Fig. 1) . Periodontal pocket samples from five different patients were also collected and analyzed. In contrast to human fecal DNA samples, all periodontal samples yielded PCR products with correct fragment sizes directly through PCR with Synergistesspecific primers. However, ambiguity-free sequences could not be obtained by direct sequencing of the PCR products, which indicated the presence of multiple sequence types. We therefore generated clone libraries from two samples (AP1156 and CP1177) and sequenced randomly selected clones (five clones per clone library). GenBank database research affirmed the affiliation of all sequence types to Synergistes, which, after phylogenetic tree reconstruction, were grouped in a separate cluster forming a unique line of descent with no close relationship to any previously cultured species (Fig. 2, cluster III) . Periodontal sequences were split into two subbranches, with seven clones grouping together (including all clones from sample CP1177), sharing approximately 96% similarity to the second periodontal subgroup (groups depicted as triangles) as well as to oral clone sequence types determined in other studies (Fig.   2 ). The overall similarity of cluster III to cluster I and cluster II was approximately 80%.
DISCUSSION
Phylogenetic diversity of SGOs of human origin. The aim of the present study was to characterize Synergistes group organisms (SGOs) isolated from clinical samples and to assess whether dominant phylotypes of SGOs could be directly detected in the human intestinal tract and the oral cavity (i.e., without the need of culturing). We discovered a remarkably high diversity of 16S rRNA gene types among the seven clinical isolates that constituted at least three different evolutionary lineages. This finding considerably expands our knowledge of medically important Synergistes clades and demonstrates that these phylotypes are principally cultivable from clinical samples. Interestingly, exploration of DNA from fecal samples with Synergistes-specific primers enabled the recovery of one sequence type directly matching with the sequence types of cluster I, the clade represented by the isolates from peritoneal fluid. To our knowledge this is not only the first evidence of SGOs being present in the human intestinal tract, but their cultivation from peritoneal fluid also suggests that SGOs could possibly be involved in the etiology of peritonitis.
In contrast to the cluster I isolates, strains of cluster II were from soft-tissue infections. The fact that both strains were found in mixed cultures (strain RMA 14551 with Aerococcus species, Morganella morganii, Proteus mirabilis, Staphylococcus epidermidis, and Porphyromonas somerae; strain RMA 10849 with alpha-hemolytic streptococci, Anaerococcus tetradius, Finegoldia magna, and Porphyromonas asaccharolytica) makes it difficult to assess the origin or the principal habitat of these SGOs.
SGOs from the periodontal pockets formed a phylogenetically separate cluster (cluster III), remote from cluster I and II but related to sequence types found in 16S rRNA gene molecular inventories from the oral microflora (7, 15) . While the sequence diversity among clones from sample CP1177 is low and might reflect interoperon variability of one particular strain, sample AP1156 consisted of at least two different phylotypes within cluster III (Fig. 2) . However, the diversity of oral SGOs is even greater, since two other (not further described) strains, "Synergistes sp. P4G_18P1" (W. G. Wade and A. de Lillo, unpublished) and "Flexistipes sp. E3_33" (15), were both isolated from the oral cavity grouped within cluster II (Fig. 2) . In fact, they were the closest relatives to the soft-tissue strains RMA 14551 and RMA 10849, respectively (Fig. 2) . Interestingly, cluster II shares a common interior branching point with cluster I (Fig. 2 ; tree topology being supported by a maximum likelihood tree). This means that the oral SGOs from cluster II are actually more closely related to the isolates from soft-tissue infections, and also to the SGOs from peritoneal fluid, rather than to their oral "partners" from cluster III. This in turn indicates the high number of Synergistes phylotypes that can be found in the oral cavity, which apparently provides several ecological niches and as such might be one major reservoir of genetic diversity for human SGOs.
Sequence-based detection of SGO. The seven clinical isolates described in this study (i.e., clusters I and II) demonstrate that at least some members of these clades are cultivable in the clinical laboratory. However, so far no cultured isolates have been described for cluster III, which is exclusively represented by clone sequences, and the ability of clinical laboratories to culture these various human phenotypes may be limited. In addition, besides being slow growing, the clinical isolates reported here proved to be biochemically inert (Table 1) , which constitutes a potential for misclassification when using biochemical test kits such as the RapID-ANA System (Table 1) . Thus, molecular methods-based approaches may be the method of choice both for enhancing our understanding of the range and nature of human-associated SGOs and for identifying potential clinical isolates.
We developed an rRNA primer system with intended target specificity for Synergistes and were able to demonstrate the presence of different phylotypes in periodontal pockets and in human feces. This primer system appears to have advantages over the primer pair used by Godon et al. (4) , since the latter did not detect SGOs in human feces even when nested PCR had been performed. Furthermore, in contrast to Godon et al. (4) , our assay detects a relatively small 16S rRNA gene fragment of approximately 600 bp in size, sufficient for genotypic identification but also suitable for quantification using realtime PCR (RTQ-PCR).
In a first attempt, we quantified SGOs in the fecal and the oral samples by RTQ-PCR using our specific primer pair, along with determination of the total microbial flora using a broad-ranged primer pair as previously described (20 and data not shown). The proportion of SGOs relative to the total microbiota was 0.01% in the fecal sample and 0.04% in the oral samples. These values are consistent with the findings of Godon et al. (4) , who found SGOs in a large variety of anaerobic ecosystems with an abundance below 1% according to the detection frequency in clone libraries. However, as determined by cultivation, the proportions of SGOs in peritoneal fluid and soft-tissue infections was higher, ranging from 0.5% to 20% according to the number of CFU of SGOs and total bacterial flora. These preliminary observations provide some support for claiming that SGOs may have a role as human pathogens. Work is currently under way to deeply assess the quantity of SGOs in defined anaerobic infectious processes (e.g., endodontic infections) by RTQ-PCR.
Final considerations. SGOs in humans are most likely involved in the anaerobic metabolism of protein amino acids, as most cultivated strains have been shown to degrade amino acids (2, 4, 11) . For instance, Synergistes jonesii, the closest relative to the isolates of cluster I, uses arginine and histidine as major energy-yielding substrates (13) and is able to detoxifiy non-protein amino acids, such as dihydroxypyridine, in the rumen of cattle (1) . Since many plants produce a variety of potentially toxic amino acids (4), niche specialization of distinct groups of SGOs in plant eaters (including humans) might be in part a function of the host's diet. Such niche adaptation might be associated with the broad diversity of SGOs throughout several environmental habitats (4) . The present study expands the view of Synergistes as a diverse and ubiquitous member of the human-associated bacterial ecosystem. The novel culture isolates now available will enable us to study their physiological properties, helping define the role that Synergistes isolates might play as human colonizers or pathogens.
